Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

17.750
-0.710-3.85%
Volume:5.21M
Turnover:91.95M
Market Cap:18.23B
PE:-20.40
High:18.300
Open:18.300
Low:17.350
Close:18.460
52wk High:38.640
52wk Low:15.250
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:1.33
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-9.32%
ROA:-2.23%
PB:2.63
PE(LYR):-20.40
PS:5.16

Loading ...

JUNSHI BIO Tables AGM Agenda: No 2025 Dividend, Up to RMB8.50 Billion Credit, RMB5.00 Billion Guarantee Quota and Fresh Mandates for Debt and Share Issuance

Bulletin Express
·
Jun 05

Junshi Bio issues proxy form for 2025 AGM; agenda covers profit distribution, financing mandates and INED election

Bulletin Express
·
Jun 05

Junshi BIO to Contribute Patent Equipment Valued at RMB 53.08 Million for Stake in Shanghai Zhiyu Biopharma, Expanding into ADC and Multi-Specific Antibody R&D

Stock News
·
Jun 05

Junshi Bio Reorganises R&D Vehicle Junyan Hongshi; Controlled VC Arm Injects RMB0.10 Billion for 9.09% Stake

Bulletin Express
·
Jun 05

Junshi Bio to Close H-Share Register 23–26 June 2026 Ahead of 2025 AGM

Bulletin Express
·
Jun 05

Shanghai Junshi Biosciences - Approved Proposal on Change in Shareholding Structure of Implementing Entity of Some Sub-Projects

THOMSON REUTERS
·
Jun 05

Shanghai Junshi Biosciences - Junyan Hongshi Intends to Increase Its Registered Capital by RMB100 Mln

THOMSON REUTERS
·
Jun 05

Junshi Biosciences Updates Board Composition and Committee Structure

Bulletin Express
·
Jun 05

JUNSHI BIO Announces 2025 Annual General Meeting Scheduled for June 26, 2026

Deep News
·
Jun 05

Junshi Bio Maintains Stable Share Base in May; 13.21 Million H-Share Options Outstanding

Bulletin Express
·
Jun 03

AH Share Premium and Deviation Rankings as of June 1st

Stock News
·
Jun 01

Junshi Biosciences Drug Meets Main Goal of Lung Cancer Study

MT Newswires Live
·
May 27

BRIEF-Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint

Reuters
·
May 26

JUNSHI BIO’s Toripalimab Hits Primary Endpoints in Phase III NEOTORCH Trial for Stage II-III NSCLC

Bulletin Express
·
May 26

JUNSHI BIO (01877): Phase III Study of Toripalimab with Chemotherapy in Perioperative Treatment for Resectable Stage II-III Non-Small Cell Lung Cancer Meets Primary Endpoints in Final Analysis

Stock News
·
May 26

Shanghai Junshi Biosciences - Toripalimab as Perioperative Treatment for Resectable Stage Ii-Iii Nsclc- Patients Met Primary Endpoint

THOMSON REUTERS
·
May 26

Junshi Biosciences Gets Nod for New Indication for Toripalimab; Shares Down 4%

MT Newswires Live
·
May 22

Shanghai Junshi Biosciences - Approval of Supplemental New Drug Application of Toripalimab

THOMSON REUTERS
·
May 21

Stock Track | JUNSHI BIO Soars 5.23% Intraday on Strong Q1 Earnings Showing Revenue Up 45% and Net Loss Narrowing Over 90%

Stock Track
·
May 11

JUNSHI BIO Nears Profitability, Yet Secondary Market Remains Skeptical: Can It Achieve Critical Valuation Rebound?

Stock News
·
Apr 29